Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues
- PMID: 17167986
Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues
Abstract
Gastric cancer cell lines express peroxisome proliferator-activated receptor gamma (PPARgamma), and treatment with PPARgamma ligands suppresses growth of subgroup of these cell lines. However, expression and subcellular distribution of PPARgamma in human gastric cancer tissues is still unknown. Therefore, expression and subcellular localization of PPARgamma were examined among different histological types of gastric cancer tissues. Immunohistochemical staining for PPARgamma was performed using biopsy specimens of human gastric cancer of various histological types, gastric adenomas, and intestinal metaplasia. All samples of intestinal metaplasia and most samples of gastric tumors, except for signet ring cell carcinoma, expressed PPARgamma in the epithelial cells. Most samples of signet ring cell cancer lacked PPARgamma expression. All samples of intestinal metaplasia expressed PPARgamma only in the cytosol. For adenoma, 90% was positive for PPARgamma in cytosol, and 40% was positive in nuclei, for well-differentiated adenocarcinoma, 80% was positive in cytosol, and 20% was positive in nuclei. For moderately differentiated adenocarcinomas, 70% was positive for cytosol, and 80% was positive for nuclei; for poorly differentiated adenocarcinoma, 30% was positive in cytosol, and 70% was positive in nuclei. The frequency of samples with positive cytosolic staining decreased as the differentiation stage turned from intestinal metaplasia to adenoma, well-, moderately-, and poorly-differentiated cancers. Simultaneously, there was a tendency toward an increased frequency of samples with positive nuclear PPARgamma staining as the differentiation stage transformed from intestinal metaplasia to poorly-differentiated cancer. There was a striking difference in subcellular localization according to the differentiation levels of gastric dysplastic cells. The findings also supported an intestinal metaplasia-adenoma-well-differentiated gastric cancer sequence, and signet ring cell cancer was suggested to be of a different lineage from other types of gastric cancers.
Similar articles
-
The role of Reg IV gene and its encoding product in gastric carcinogenesis.Hum Pathol. 2010 Jan;41(1):59-69. doi: 10.1016/j.humpath.2009.06.013. Epub 2009 Sep 8. Hum Pathol. 2010. PMID: 19740514
-
Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists.Br J Cancer. 2000 Nov;83(10):1394-400. doi: 10.1054/bjoc.2000.1457. Br J Cancer. 2000. PMID: 11044367 Free PMC article.
-
Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases.Chin Med J (Engl). 2007 Sep 5;120(17):1498-504. Chin Med J (Engl). 2007. PMID: 17908458
-
Genetic pathways of two types of gastric cancer.IARC Sci Publ. 2004;(157):327-49. IARC Sci Publ. 2004. PMID: 15055305 Review.
-
Gastric adenocarcinoma of fundic gland type with signet-ring cell carcinoma component: A case report and review of the literature.World J Gastroenterol. 2018 Jul 14;24(26):2915-2920. doi: 10.3748/wjg.v24.i26.2915. World J Gastroenterol. 2018. PMID: 30018486 Free PMC article. Review.
Cited by
-
The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain.Mol Cell Biol. 2011 Aug;31(16):3497-510. doi: 10.1128/MCB.01421-10. Epub 2011 Jun 20. Mol Cell Biol. 2011. PMID: 21690289 Free PMC article.
-
Peroxisome proliferator-activated receptor-α expression is associated with histological type in human gastric carcinoma.Mol Clin Oncol. 2022 Feb;16(2):51. doi: 10.3892/mco.2021.2484. Epub 2021 Dec 24. Mol Clin Oncol. 2022. PMID: 35070300 Free PMC article.
-
Chemotherapy and chemoprevention by thiazolidinediones.Biomed Res Int. 2015;2015:845340. doi: 10.1155/2015/845340. Epub 2015 Mar 19. Biomed Res Int. 2015. PMID: 25866814 Free PMC article. Review.
-
Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.World J Gastroenterol. 2009 Jan 28;15(4):441-8. doi: 10.3748/wjg.15.441. World J Gastroenterol. 2009. PMID: 19152448 Free PMC article.
-
Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway.FASEB J. 2019 Dec;33(12):13710-13721. doi: 10.1096/fj.201901388R. Epub 2019 Oct 4. FASEB J. 2019. PMID: 31585508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical